Spectral AI (MDAI) said Monday that a 164-patient study showed that its AI-powered DeepView burn assessment system outperformed the clinical judgment of burn physicians by a large margin.
The study, which began in January 2024 and ended this month, showed the DeepView System scored 86.6% in terms of image sensitivity while clinical judgment annotation of burn physicians scored 40.8%, the company said.
The Deepview System also outperformed the anticipated results for image-wise specificity in segmenting non-healing wound areas with a 61.2% score, versus an anticipated result of 36.0% by physicians, the company said.
Spectral AI said it plans to submit the results to the US Food and Drug Administration by the end of Q2.
Shares of the company were up around 9% in premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.